[CLAIMS]

[Claim 1]

A liquid composition for use in stabilizing botulinum toxin, which comprises polysorbate 80, methionine and serine as active ingredients, and

wherein the composition comprises 0.01 mg/mL or more of polysorbate 80 per 40 U/mL of botulinum toxin.

[Claim 2]

The composition of claim 1, wherein the composition ratio of polysorbate 80 : serine: methionine is 1 (mg/mL): 5 to 50 (mM) : 0.2 (mM).

[Claim 3]

A pharmaceutical composition in liquid formulation, comprising the liquid composition for use in stabilizing botulinum toxin of claim 1 or 2; and botulinum toxin as active ingredients.

[Claim 4]

The pharmaceutical composition of claim 3, wherein the concentration of serine is 5 mM or more per 40 units of the botulinum toxin.

[Claim 5]

The pharmaceutical composition of claim 3, wherein the concentration of methionine is less than 0.5 mM per 40 units of the botulinum toxin.

[Claim 6]

The pharmaceutical composition of claim 3, wherein the botulinum toxin is selected from the group consisting of botulinum type A, B, C, D, E, F and G.

o

[Claim 7]

The pharmaceutical composition of claim 3, wherein the botulinum toxin is a form that does not contain a complexing protein or a complex form that contains a complexing protein.

[Claim 8]

A method for stabilizing botulinum toxin, comprising:

mixing a liquid composition comprising polysorbate 80, methionine and serine with botulinum toxin, and

wherein the composition comprises 0.01 mg/mL or more of polysorbate 80 per 40 U/mL of botulinum toxin.

o